Intermediate-Size Expanded Access: how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Intermediate-Size EA is

Origin and authorising body. United States Food and Drug Administration, 21 CFR 312.315 (intermediate-size patient population expanded access). The authorising body for each individual case is the United States Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER), with parallel destination-country regulator review for any cross-border supply, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. 21 CFR 312.315 authorises expanded access for an intermediate-size patient population. The population is defined as larger than a single individual patient but smaller than the population that would be served by a Treatment IND. The framework applies when a drug is not being developed (often because the disease is so rare that adequate development is not possible) or when the drug is being developed but enrolment in a trial is not feasible or expected to be sufficient. The mechanism is one of the three tiers of FDA Expanded Access under 21 CFR 312 Subpart I.

Intermediate-Size Expanded Access is the middle tier of FDA Expanded Access between the Single Patient IND and the Treatment IND. It is used when a patient group is small enough that a Treatment IND is not warranted but large enough that individual Single Patient INDs would be administratively impractical. Typical scenarios: an ultra-rare disease with two dozen US patients, a regional cluster of cases that does not justify a national trial, or a paediatric subset of an adult-approved drug. The framework permits a single written protocol covering the cohort while preserving the case-by-case clinical-need basis of expanded access.

The sponsor (typically the manufacturer) submits a protocol describing the patient population, the rationale for using the intermediate-size mechanism rather than a trial, the eligibility criteria, the monitoring plan, and the adverse event reporting plan. Each treating physician enrols qualifying patients under the protocol with concurrent IRB review at the dispensing site. The cohort size is not fixed in regulation but is typically in the range of dozens to a few hundred patients. For cross-border enrolment, the FDA-side authorisation pairs with a destination-country named-patient or compassionate-use permit on the receiving side.

This page consolidates Reserve Meds's operational view of the Intermediate-Size Expanded Access framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Intermediate-Size Expanded Access-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Intermediate-Size EA

Intermediate-Size Expanded Access is used when the patient population is defined and bounded (ultra-rare disease, narrow paediatric subset, specific clinical scenario) and when neither a Single Patient IND for each patient nor a full Treatment IND is the right operational fit. The treating physician must confirm each patient meets the protocol's eligibility criteria, must obtain informed consent, and must operate under the cohort protocol's monitoring and reporting requirements. Cross-border patients can be enrolled where the protocol permits international enrolment and where the destination country grants a parallel permit.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Intermediate-Size EA

Ultra-rare disease therapies (gene therapies for diseases affecting fewer than a few thousand patients globally), paediatric formulations of adult-approved drugs in defined paediatric subsets, investigational drugs for regional disease clusters, and investigational therapies where formal trial enrolment is not feasible because the eligible population is too small or geographically dispersed.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Intermediate-Size Expanded Access import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Intermediate-Size Expanded Access framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Intermediate-Size Expanded Access dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Intermediate-Size Expanded Access clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Intermediate-Size Expanded Access authorisation as the legal basis for import but does recognise a Intermediate-Size Expanded Access authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Intermediate-Size EA application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Sponsor-held intermediate-size expanded access IND with cohort protocol approved by the FDA.
• Patient clinical history confirming eligibility per the protocol.
• Informed consent compliant with the cohort protocol and 21 CFR 50.
• Local IRB review and approval at the dispensing site.
• Monitoring and adverse event reporting per the protocol.
• For cross-border supply: destination-country named-patient or compassionate-use application in parallel.
• Periodic safety and outcomes reporting from the sponsor to the FDA per the IND.

Typical timeline

Initial IND review by the FDA: 30-day clock for new submissions, longer for protocol amendments. Once the cohort IND is open, enrolment of qualifying patients runs on local IRB review timelines (2 to 4 weeks) plus the destination-country named-patient permit timeline (5 to 25 business days). End-to-end, most patients complete enrolment within 4 to 8 weeks from referral. Patients enrolling after the cohort has been operating for some time typically clear faster because IRB precedent and supply logistics are already established.

Costs and reimbursement

Cost recovery under 21 CFR 312.8 is permitted but not automatic. Some manufacturers provide cohort drugs free as a managed-access policy; some charge cost-recovery prices. International logistics, customs, dispensing handling, and coordinator fees apply for cross-border supply. Insurer reimbursement for investigational cohort drugs is uncommon, and patients should plan on a cash-pay basis unless the manufacturer's programme covers drug cost.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Intermediate-Size Expanded Access cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Intermediate-Size Expanded Access framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works